View Older Stories View More Recent Stories

Mar 2, 2026 08:01AM Rallybio and Candid Therapeutics announce merger agreement
Feb 17, 2026 04:09PM Form 13F-HR venBio Partners LLC For: Dec 31
Feb 4, 2026 09:03PM Form SCHEDULE 13D/A ALX ONCOLOGY HOLDINGS Filed by: venBio Global Strategic Fund, L.P.
Jan 30, 2026 08:31AM ALX Oncology prices $150 million stock and warrant offering
Jan 27, 2026 07:30AM Lexeo Therapeutics names new chief medical officer
Dec 17, 2025 08:01AM VYNE Therapeutics and Yarrow Bioscience announce merger agreement
Nov 17, 2025 01:13PM Form SCHEDULE 13G/A ALUMIS INC. Filed by: venBio Global Strategic Fund IV, L.P.
Nov 14, 2025 04:28PM Form 13F-HR venBio Partners LLC For: Sep 30
Sep 2, 2025 04:58PM Form N-PX venBio Partners LLC For: Jun 30
Aug 14, 2025 04:22PM Form 13F-HR venBio Partners LLC For: Jun 30
May 15, 2025 04:45PM Form SCHEDULE 13G/A Artiva Biotherapeutics, Filed by: venBio Global Strategic Fund III, L.P.
May 15, 2025 04:18PM Form 13F-HR venBio Partners LLC For: Mar 31
Apr 11, 2025 08:29AM Form D OCA venBio IV Segregated
Feb 14, 2025 04:26PM Form 13F-HR venBio Partners LLC For: Dec 31
Nov 14, 2024 04:56PM Form SC 13G/A Artiva Biotherapeutics, Filed by: venBio Global Strategic Fund III, L.P.
Nov 14, 2024 04:20PM Form 13F-HR venBio Partners LLC For: Sep 30
Sep 3, 2024 04:33PM Form N-PX venBio Partners LLC For: Jun 30
Aug 14, 2024 04:13PM Form 13F-HR venBio Partners LLC For: Jun 30
Aug 8, 2024 09:06PM Form SC 13D/A Elevation Oncology, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Aug 1, 2024 07:00PM Form SC 13G Artiva Biotherapeutics, Filed by: venBio Global Strategic Fund III, L.P.
Jul 19, 2024 01:58PM Form D OCA VenBio V LLC
Jul 12, 2024 11:19AM Form D venBio Global Strategic
Jul 11, 2024 04:30PM Form SC 13G ALUMIS INC. Filed by: venBio Global Strategic Fund IV, L.P.
May 15, 2024 04:40PM Form 13F-HR venBio Partners LLC For: Mar 31
May 9, 2024 07:30AM Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
Mar 28, 2024 09:00AM AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING
Mar 6, 2024 08:00AM Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
Mar 1, 2024 07:00AM FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio
Feb 21, 2024 09:00AM Insamo Launches with $12M Funding from Playground Global, venBio, and MRL Ventures Fund to Develop Best-in-Class Membrane-Permeable Macrocyclic Peptides
Feb 21, 2024 07:00AM NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
Feb 14, 2024 04:42PM Form 13F-HR venBio Partners LLC For: Dec 31
Feb 9, 2024 04:41PM RayzeBio (RYZB): venBio Global Strategic Fund III Reports 8.5% Passive Stake
Feb 9, 2024 04:38PM Form SC 13G RayzeBio, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Feb 6, 2024 07:00AM Attralus Closes $56 Million Financing
Jan 29, 2024 08:36AM New Company Eyconis Formed to Develop Ascendis Pharma (ASND) Ophthalmology Assets with $150 Million Commitment from External Investors
Jan 29, 2024 08:30AM New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
Jan 25, 2024 06:05AM Form SC 13D/A Pharvaris N.V. Filed by: venBio Global Strategic Fund III, L.P.
Nov 14, 2023 08:11PM Form 13F-HR venBio Partners LLC For: Sep 30
Nov 10, 2023 09:00AM NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting
Oct 17, 2023 07:00AM NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease
Sep 21, 2023 04:31PM Form 4 RayzeBio, Inc. For: Sep 19 Filed by: venBio Global Strategic Fund III, L.P.
Aug 14, 2023 04:33PM Form 13F-HR venBio Partners LLC For: Jun 30
Aug 7, 2023 06:50AM Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 2, 2023 04:15PM Horizon Technology Finance (HRZN) Provides $15M Venture Loan Facility to Tallac Therapeutics
Aug 2, 2023 04:15PM Horizon Technology Finance Provides $15 Million Venture Loan Facility to Tallac Therapeutics
Jun 21, 2023 04:33PM Form SC 13D/A Pharvaris N.V. Filed by: venBio Global Strategic Fund III, L.P.
Jun 20, 2023 07:30AM Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform
Jun 20, 2023 06:53AM Pharvaris (PHVS) Announces $70M Private Placement
Jun 20, 2023 06:50AM Pharvaris Announces $70 Million Private Placement Financing
Jun 15, 2023 04:31PM Form SC 13D/A Elevation Oncology, Inc. Filed by: venBio Global Strategic Fund III, L.P.
View More Recent Stories View Older Stories